⌕
Xenon Pharmaceuticals · XENE · Nasdaq
Tenet 44 · Weak
Compare
$38.78−1.22%At closeTenet 44 · Weak
$38.78−0.48 (−1.22%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Xenon Pharmaceuticals (XENE) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 59% below its peak, net margin −4612.1%. Worth your attention in FY25: Share count (+81.7%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
7.5
FY21→FY25CAGR −20.1%/yr
Net income ($M)▼47.6%
−345.9
FY21→FY25CAGR —
Free cash flow ($M)▼51.7%
−279.9
FY21→FY25CAGR —
Diluted EPS▼44.9%
−4.36
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+81.7%

43.6mn → 79.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$799.0K

−74.0% YoY in FY25 · 10.7% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)7.5Revenue0.0COGS−300.9R&D−79.6SG&A−373.1Op income27.2Tax & other−345.9Net income

-4612¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -4612.1% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7944, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—7,500.00.00.09,434.018,437.0—−20.1%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
——A0.00.0—A18,437.0——
Research & development
371,076.0300,938.0210,394.0167,512.0105,767.075,463.0▲43.0%+41.3%
Selling, general & admin
94,241.079,632.068,904.046,542.032,810.021,967.0▲15.6%+38.0%
Total operating expenses
465,317.0380,570.0279,298.0214,054.0138,577.097,430.0▲36.3%+40.6%
Operating incomefeeds ROC rank
−465,317.0−373,070.0−279,298.0−214,054.0−129,143.0−78,993.0▼33.6%—
Other income, net
35,808.028,176.040,879.031,369.03,888.0105.0——
Pretax income
−429,509.0−344,894.0−238,419.0−182,685.0−125,255.0−78,888.0▼44.7%—
Income tax
−775.01,016.0−4,089.0−292.0118.0−6.0—+105.0% (22→25)
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−428,734.0−345,910.0−234,330.0−182,393.0−124,936.0−78,882.0▼47.6%—
Per share
Diluted EPSbuyback-sensitive
−4.70−4.36−3.01−2.73−2.06−1.77▼44.9%—
Diluted shares (mn)
99.7779.2577.8966.8960.5443.63▲1.7%+16.1%
Margins
Gross margin
——A———A100.0%——
Operating margin
—−4974.3%——−1368.9%−428.4%——
Net margin
—−4612.1%——−1324.3%−427.8%——
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY12 – FY20 · 9 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 9 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Xenon Pharmaceuticals' net income?

Xenon Pharmaceuticals reported net income of −$345.9M in fiscal 2025, a net margin of −4612.1%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.